Carlsmed, Inc. (NASDAQ:CARL) Stock Has Consensus Target Price of $19.25

Carlsmed, Inc. (NASDAQ:CARL) has received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $19.25.

Several research analysts have commented on the stock. Needham & Company LLC started coverage on shares of Carlsmed in a research note on Wednesday, July 1st. They set a “buy” rating and a $17.00 price target on the stock. Truist Financial increased their target price on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings raised shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, BTIG Research restated a “buy” rating and set a $23.00 price target on shares of Carlsmed in a research report on Monday, September 28th.

Carlsmed Trading Up 2.6%

Shares of CARL stock opened at $14.42 on Friday. The business has a 50-day moving average price of $14.93 and a two-hundred day moving average price of $12.24. Carlsmed has a 12-month low of $8.50 and a 12-month high of $17.23. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The firm has a market cap of $393.71 million, a P/E ratio of -10.08 and a beta of 2.09.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The company had revenue of $18.94 million for the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. Equities analysts anticipate that Carlsmed will post -1.50 EPS for the current fiscal year.

Hedge Funds Weigh In On Carlsmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new position in Carlsmed in the 2nd quarter worth approximately $12,992,000. Janus Henderson Group PLC grew its holdings in shares of Carlsmed by 7.6% in the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after purchasing an additional 86,834 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of Carlsmed in the second quarter worth $6,200,000. BlackRock Inc. bought a new stake in Carlsmed during the 2nd quarter valued at $5,528,000. Finally, KCM Capital Inc bought a new stake in Carlsmed during the 1st quarter valued at $1,810,000.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.